FilingReader Intelligence

Hester Biosciences consolidated profit surges 131% despite standalone decline

August 1, 2025 at 06:59 AM UTCBy FilingReader AI

Hester Biosciences reported mixed Q1 FY26 results with standalone product sales down 14% and profit declining 7%.

However, consolidated net profit surged 131% to INR 172.96 million, driven by Hester Africa's turnaround. Consolidated divisional product sales grew 2% to INR 840.89 million.

The Animal Healthcare division faced a 33% sales decline due to program delays.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

BSE:HESTERBIOBombay Stock Exchange

News Alerts

Get instant email alerts when Hester Biosciences publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →